TP53 and cancer: In cancer cells (HepG2 and Human embryonic kidney 293Acells with high basal JNK (C-Jun N-terminal kinase) activity), EEDK leads to JNK-AP-1/p53-mediated cancer cell death by activating the PDGFR-Rac-JNK signaling axis [99].